<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03719924</url>
  </required_header>
  <id_info>
    <org_study_id>PRODIGE 62 - OESIRI</org_study_id>
    <nct_id>NCT03719924</nct_id>
  </id_info>
  <brief_title>Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma</brief_title>
  <acronym>OESIRI</acronym>
  <official_title>Nal-IRI/LV5-FU VERSUS PACLITAXEL AS SECOND-LINE THERAPY IN PATIENTS WITH METASTATIC OESOPHAGEAL SQUAMOUS CELL CARCINOMA A Multi-centre, Randomized, Non-comparative Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Federation Francophone de Cancerologie Digestive</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our study is to evaluate the efficacy and safety of NALIRI plus 5FU versus&#xD;
      paclitaxel as a second-line therapy in patients with locally advanced or metastatic ESCC who&#xD;
      had failed to cisplatin- or oxaliplatin-based first-line chemotherapy.&#xD;
&#xD;
      The hypotheses are as follows:&#xD;
&#xD;
      H0: the percentage of patients alive at 9 months of 40% is not useful. H1: the percentage of&#xD;
      patients alive at 9 months of 60% is expected.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Principal objective:&#xD;
&#xD;
      • To evaluate the survival of patients at 9 months&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  Progression-free survival (PFS) (clinical and/or radiological)&#xD;
&#xD;
        -  Overall survival (OS)&#xD;
&#xD;
        -  Best response rate during treatment according to RECIST 1.1 criteria (according to the&#xD;
           investigator and the centralised review committee)&#xD;
&#xD;
        -  Toxicity (NCI CTC 4.0)&#xD;
&#xD;
        -  Quality of life (QLQ-C30 and OES18 questionnaires of the EORTC)&#xD;
&#xD;
      Arm A (experimental arm): Nal IRI plus LV5-FU (D1=D28) Nal-IRI: 80 mg/m² intravenous over 90&#xD;
      minutes Followed by intravenous folinic acid 400 mg/m² over 30 minutes or L-folinic acid: 200&#xD;
      mg/m² over 30 minutes And then 5-FU 2,400 mg/m² over 46 hours on D1 to D14 Patients known to&#xD;
      be homozygous for the UGT1A1*28 allele who are to be randomized to the Nal-IRI/5-FU Arm&#xD;
      receive the first cycle of therapy with a reduced dose of Nal IRI of 60 mg/m2. If the patient&#xD;
      does not present any toxicity related to the medicinal product after the first administration&#xD;
      of Nal IRI, the dose can be increased to 80 mg/m2 starting with cycle 2.&#xD;
&#xD;
      Arm B (control arm): PACLITAXEL (D1=D28) Paclitaxel: 80 mg/m² at D1, D8 and D15&#xD;
&#xD;
      Patients will be randomized in a 1:1 ratio using the minimisation technique. Randomisation&#xD;
      will be stratified based on the following factors:&#xD;
&#xD;
        -  Centre&#xD;
&#xD;
        -  WHO performance status: 0/1 versus 2&#xD;
&#xD;
      An analysis of circulating tumour DNA (using genetic mutations, in particular, TP53, and DNA&#xD;
      methylation analyses) will be performed before the 1st cycle of treatment and at D28, in&#xD;
      order to look for factors predictive of response to treatment (decrease in unbound DNA).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 7, 2019</start_date>
  <completion_date type="Anticipated">April 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All initial characteristics will be described in the overall population and by treatment arm. Evaluation criteria related to efficacy and safety will be described by treatment arm. Initial characteristics of best response and toxicities will be evaluated using usual statistics: for quantitative variables: mean, standard deviation, median, interquartile interval and range and for qualitative variables: frequencies and percentages.&#xD;
For the primary evaluation end point, a one-sided 95% confidence interval (CI) will be calculated in the experimental arm.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>survival at 9 months</measure>
    <time_frame>9 months</time_frame>
    <description>The principal objective is to evaluate survival at 9 months in patients presenting with metastatic oesophageal squamous cell carcinoma (OSC) treated with Nal-IRI/LV5-FU or with paclitaxel.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Clinical Progression-free survival and/or radiological Progression free survival will be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>1 year</time_frame>
    <description>evaluate the overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best response rate during treatment</measure>
    <time_frame>6 months</time_frame>
    <description>Best response rate during treatment according to RECIST 1.1 criteria (according to the investigator and with centralised review)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity (NCI-CTC v4)</measure>
    <time_frame>6 months</time_frame>
    <description>all observed toxicities, graded according to NCI-CTC v4 and the SAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (questionnaires)</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of life (QLQ-C30 questionnaires of EORTC) and OES18 questionnaires of EORTC</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>arm A: ONIVYDE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ONIVYDE ONIVYDE will be administered first, followed by folinic acid or L-folinic acid and then 5-FU at D1 and D14 ONIVYDE: 80 mg/m² intravenous over 90 minutes Folinic acid: 400 mg/m² intravenous over 30 minutes or L-folinic acid (racemic form L) 200 mg/m² over 30 minutes 5-FU: 2400 mg/m² over 46 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: TAXOL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TAXOL Premedication consists of corticosteroids, H1 antihistamines and H2 antagonists during 30 minutes at time 1 hour before chemotherapy One cycle every 28 days (D1=D28) 80 mg/m2 IV over 60 minutes at D1, D8 and D15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Onivyde</intervention_name>
    <description>onivyde will be administered first, followed by folinic acid or L-folinic acid and then 5-FU at D1 and D14.</description>
    <arm_group_label>arm A: ONIVYDE</arm_group_label>
    <other_name>no other intervention name to add</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel : 80 mg/m2 IV during 60 minutes at D1, D8 and D15</description>
    <arm_group_label>Arm B: TAXOL</arm_group_label>
    <other_name>no other intervention name to add</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven metastatic oesophageal squamous cell carcinoma&#xD;
&#xD;
          -  Patient in failure with 1st-line treatment with oxaliplatin or cisplatin. Patients&#xD;
             presenting with resectable disease treated with surgery or neoadjuvant or adjuvant&#xD;
             chemotherapy with oxaliplatin or cisplatin (with or without radiotherapy) can be&#xD;
             included if a recurrence has occurred less than 6 months after the end of treatment&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Unresectable disease, measurable or not, according to RECIST 1.1 criteria&#xD;
&#xD;
          -  WHO performance status ≤ 2&#xD;
&#xD;
          -  Neutrophils ≥ 1500/mm3 (without use of haematopoietic growth factors), platelets ≥ 100&#xD;
             000/mm3, haemoglobin ≥ 9 g/dl (blood transfusions are authorised for patients with a&#xD;
             haemoglobin less than 9 g/dl)&#xD;
&#xD;
          -  Total bilirubin ≤ 2 x ULN (biliary drainage is authorised in case of a biliary&#xD;
             obstruction); albumin ≥ 25 g/L; AST ≤ 2.5 x ULN, and ALT ≤ 2.5 x ULN (≤ 5 x ULN in&#xD;
             case of hepatic metastases)&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 ml/min according to MDRD formula&#xD;
&#xD;
          -  A normal ECG or ECG with no clinically significant findings&#xD;
&#xD;
          -  Patient able to understand and to sign the informed consent form (or who has a legal&#xD;
             guardian able to do so for him/him)&#xD;
&#xD;
          -  Women of childbearing potential must have a negative pregnancy blood or urine test&#xD;
             within 7 days prior to inclusion&#xD;
&#xD;
          -  Women of childbearing potential, as well as men (who have sexual relations with women&#xD;
             of childbearing potential) must agree to use an effective method of contraception&#xD;
             throughout this study and during the 6 months following administration of the last&#xD;
             dose of the study medicinal product&#xD;
&#xD;
          -  Patient who is a beneficiary of the Social security system&#xD;
&#xD;
          -  Patient for whom regular follow-up is possible.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known brain or bone metastases&#xD;
&#xD;
          -  Clinically significant gastrointestinal disorders, including hepatic, haemorrhagic,&#xD;
             inflammatory, obstructive disorders or diarrhoea &gt; grade 1&#xD;
&#xD;
          -  History of chronic inflammatory bowel disease&#xD;
&#xD;
          -  Gilbert's syndrome&#xD;
&#xD;
          -  Interstitial lung disease&#xD;
&#xD;
          -  Treatment with St John's Wort&#xD;
&#xD;
          -  Medical history of Whipple procedure&#xD;
&#xD;
          -  Body mass index &lt; 18.5 kg/m2&#xD;
&#xD;
          -  Combination with sorivudine and others analogues as brivudine (irreversibly inhibits&#xD;
             the enzyme dihydropyrimidine dehydrogenase)&#xD;
&#xD;
          -  History of progressive cancer or in remission of less than 3 years duration (patients&#xD;
             who present with a cancer in situ or basal cell or squamous cell skin cancer during&#xD;
             the last 3 years are eligible).&#xD;
&#xD;
          -  Severe arterial thromboembolic events (myocardial infarction, unstable angina, stroke)&#xD;
             less than 3 months before inclusion&#xD;
&#xD;
          -  NYHA class III or IV congestive heart failure, ventricular arrhythmia or uncontrolled&#xD;
             blood pressure&#xD;
&#xD;
          -  Significant neuropathy ≥ grade 2 according to NCI CTCAE criteria (National Cancer&#xD;
             Institute Common Terminology Criteria for Adverse Events) v.4.0.&#xD;
&#xD;
          -  Known hypersensitivity or allergy to a component of the medicinal products used in the&#xD;
             study.&#xD;
&#xD;
          -  Known DPD deficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DAVID TOUGERON</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRODIGE 62 - FFCD 1701</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>DAVID TOUGERON</last_name>
    <phone>05.49.44.37.51</phone>
    <phone_ext>42109</phone_ext>
    <email>David.TOUGERON@chu-poitiers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VINCENT HAUTEFEUILLE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>laurent mineur</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Européen</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yves rinaldi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ch Le Raincy</name>
      <address>
        <city>Montfermeil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>IDA PAVESE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>THOMAS APARICIO</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ch Perpignan</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chu de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DAVID TOUGERON, PR</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PIERRE MICHEL</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ch Duchenne</name>
      <address>
        <city>Saint-Malo</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ROMAIN DESGRIPPES</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Randrian V, Adenis A, Desrame J, Barbier E, Di Fiore F, Lièvre A, Dahan L, Laurent-Puig P, Mineur L, Breysacher G, Roquin G, Louafi S, Lopez A, Louvet C, Borg C, Metges JP, Faroux R, Gaba L, Manfredi S, Tougeron D. Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study. Dig Liver Dis. 2020 Mar;52(3):347-350. doi: 10.1016/j.dld.2019.11.014. Epub 2019 Dec 30.</citation>
    <PMID>31899122</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 26, 2018</study_first_submitted>
  <study_first_submitted_qc>October 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ESCC NAL-IRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

